ADMA Biologics Inc (NASDAQ:ADMA) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048,946 shares of the biotechnology company's stock after buying an additional 207,097 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.29% of ADMA Biologics worth $59,211,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics in the 4th quarter worth $35,000. Farther Finance Advisors LLC grew its position in shares of ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the period. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter worth about $51,000. AlphaQuest LLC purchased a new position in ADMA Biologics in the 4th quarter valued at about $84,000. Finally, GF Fund Management CO. LTD. purchased a new position in ADMA Biologics in the 4th quarter valued at about $85,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA traded up $0.16 during midday trading on Thursday, hitting $18.30. The company's stock had a trading volume of 1,053,349 shares, compared to its average volume of 3,693,451. The company has a market cap of $4.37 billion, a P/E ratio of 21.52 and a beta of 0.43. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67. The business's 50 day simple moving average is $20.40 and its 200 day simple moving average is $18.73. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period last year, the business earned $0.08 earnings per share. On average, analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on ADMA. Raymond James Financial boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

Insider Buying and Selling

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.